Primary antibodies used were from Cell Signalling unless otherwise mentioned:
β-actin (Abcam #ab6276),
cleaved PARP (#5625), CDK1 Y15 (#9111), CHK1 (#2360), CHK1 S345 (#2348), H2AX (#7631),
H2AX S139 (Millipore #05-636), H3 (#9715), H3 S10 (#3377), RRM2 (ABNOVA #H00006241-M01), ATR (Santa Cruz #1887), ATR T1989 (Gene Tex #GTX128145), CHK2 (#2662), CHK2 T68 (Abcam #3501), KAP1 (Abcam #10484), KAP1 S824 (Abcam #133440),
DNA-PKcs (Abcam #70250),
DNA-PKcs S2056 (Abcam #18192), ATM (Abcam #78),
ATM S1981 (Abcam #81292),
RPA32 (Abcam #2175),
RPA32 S4/8 (Bethyl Laboratories #A300-245A),
RPA32 S33 (Bethyl Laboratories #A300-246A).
For secondary antibodies,
Alexa 488 (#4408, #4412) and
Alexa 647 (#4410, #4414) from Cell Signalling were used in immunostaining.
IRDye800-conjugated (#925-32210, #926-33210) and
IR680-conjugated (#926-68070, #926-68021) antibodies from LICOR were used in immunoblotting.
Wallez Y., Dunlop C.R., Johnson T.I., Koh S.B., Fornari C., Yates J.W., Bernaldo de Quirós Fernández S., Lau A., Richards F.M, & Jodrell D.I. (2018). The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Molecular cancer therapeutics, 17(8), 1670-1682.